Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia

Authors

  • Li Zhang MD,

    1. Department of Pediatrics, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China
    Search for more papers by this author
  • Zeng Cao MD,

    1. Department of Pediatrics, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China
    Search for more papers by this author
  • Min Ruan MD,

    1. Department of Pediatrics, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China
    Search for more papers by this author
  • Qiang Zeng MD,

    1. Tianjin Centers for Disease Control and Prevention, Tianjin, P.R. China
    Search for more papers by this author
  • Liang Zhao MD,

    1. Tianjin Centers for Disease Control and Prevention, Tianjin, P.R. China
    Search for more papers by this author
  • Qinghua Li MD,

    1. Department of Pediatrics, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China
    Search for more papers by this author
  • Yao Zou MD,

    1. Department of Pediatrics, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China
    Search for more papers by this author
  • Jianxiang Wang MD,

    1. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China
    Search for more papers by this author
  • Xiaofan Zhu MD

    Corresponding author
    1. Department of Pediatrics, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China
    • Correspondence to: Xiaofan Zhu, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin 300020, P.R. China.

      E-mail: xfzhu1981@126.com

    Search for more papers by this author

  • Conflict of interest: The authors declare no conflict of interest.

Abstract

Background

To determine the prognostic significance of the detection of the minimal residual disease (MRD) in children with AML1/ETO AML, we compared the results of reverse-transcription polymerase chain reaction (RT-PCR) and quantitative reverse-transcription polymerase chain reaction (RQ-PCR).

Procedure

Between January 2006 and February 2013, 70 patients (≤16 years of age) with AML1/ETO AML were included in our study. Bone marrow samples were evaluated using by both RT-PCR and RQ-PCR assays. AML1/ETO transcripts were normalized to 105 ABL copies.

Results

When treated with fewer than four courses of therapy, no association was found between positive RT-PCR results and relapse. After four courses of therapy, a positive RT-PCR result was correlated with a probability of relapse. After induction chemotherapy, a >1.8 log reduction in AML1/ETO transcripts in BM determined by RQ-PCR may represent a subgroup of patients at low risk for relapse. MRD levels after consolidation (Courses 2 and 3) were also informative.

Conclusion

Both RT-PCR and RQ-PCR can be used to detect MRD in childhood AML1/ETO AML. RQ-PCR can identify patients who are at high risk of relapse earlier than can RT-PCR. Pediatr Blood Cancer 2014; 61:1761–1766. © 2014 Wiley Periodicals, Inc.

Ancillary